Test

Hardest Haematology ST3 Interview Questions and Answers

Medical Interview Specialists

Some Haematology ST3 interview questions are difficult because they require more than recall. They test whether you can manage uncertainty, balance competing risks, escalate appropriately, and communicate honestly in emotionally charged situations. The strongest candidates are not those who give the most dramatic answers, but those who remain structured, safe and thoughtful when the scenario is complex.

Why Hard Questions Matter

Haematology is full of high-stakes clinical judgement: bleeding versus thrombosis, urgent treatment versus diagnostic accuracy, intensive therapy versus frailty, and patient autonomy versus clinical concern. Difficult interview questions are designed to test how you think under pressure. A good answer should show prioritisation, senior support, ethical awareness and practical next steps.

Haematology ST3 Interview Online Course

Techniques, Tutorials & More Designed To Ensure Optimal Performance

Question Bank

Our Question Bank Is Designed To Reflect Real-Life Interview Questions

Free Resources

Access All BlackStone Tutors’ Free Resources Here

The Difficult Questions

A patient with suspected primary CNS lymphoma has significant neurological symptoms. Neurosurgery want a biopsy tomorrow, but the medical team ask whether to start dexamethasone now. What do you do?

This is a difficult balance because steroids may improve neurological symptoms but can also compromise diagnostic yield in lymphoma. I would first assess the immediate clinical risk: level of consciousness, focal neurology, signs of raised intracranial pressure and imaging evidence of mass effect. If there were life-threatening neurological compromise, steroids may be necessary despite the diagnostic risk.

If the patient were clinically stable and biopsy was imminent, I would avoid steroids until tissue diagnosis if possible, after discussion with haematology, neurosurgery and oncology. I would ensure the decision was made at senior level, documented clearly, and communicated to the patient. The key is not to apply a rigid rule, but to balance urgent neurological safety against the need for accurate diagnosis.

A patient with capacity refuses blood transfusion during major haemorrhage because they are a Jehovah’s Witness. How do you respond?

A capacitous adult has the right to refuse blood products, even if that refusal may result in death. I would confirm capacity, clarify the exact nature of the refusal, check for an advance decision and explore which products or interventions the patient would accept. Some patients may accept cell salvage, tranexamic acid, iron, erythropoietin, fibrinogen concentrate or other factor concentrates, while others may not.

I would involve senior haematology, anaesthetics and the treating specialty urgently. I would manage the haemorrhage using all acceptable alternatives and document the discussion carefully. I would not try to coerce the patient or frame refusal as irrational. My role is to ensure the decision is informed, voluntary and respected, while doing everything possible within the patient’s stated boundaries.

You suspect TTP, but the ADAMTS13 result will not be available until tomorrow. The patient has thrombocytopenia, haemolysis and confusion. What do you do?

I would treat this as TTP until proven otherwise. TTP is a haematological emergency, and waiting for ADAMTS13 confirmation can be dangerous. I would involve the haematology consultant urgently and arrange transfer or treatment discussion for plasma exchange and immunosuppression according to local pathway.

I would send ADAMTS13 before plasma therapy if this could be done without delaying treatment. I would also assess cardiac, renal and neurological involvement, send haemolysis markers, coagulation screen and troponin, and monitor closely. I would avoid platelet transfusion unless there was life-threatening bleeding. This answer should show that I understand both the diagnostic uncertainty and the urgency of early treatment.

A patient with relapsed AML is frail and their family want “everything done”, but you think intensive treatment may cause more harm than benefit. How would you approach this?

I would first clarify the clinical facts: disease status, performance status, comorbidities, organ function, previous treatment response and realistic treatment options. I would discuss the case with the consultant and MDT, because decisions about relapsed AML and treatment intensity should not be made in isolation.

In conversation with the patient and family, I would explore what they understand and what matters most to the patient. I would explain that “everything” should mean everything appropriate and beneficial, not treatments that are very unlikely to help and may cause suffering. I would discuss alternatives such as lower-intensity therapy, transfusion support, infection management and palliative care involvement alongside active haematology care. If the patient has capacity, their values should guide the decision, but they need honest information about benefit and burden.

You discover that a patient received non-irradiated blood despite having a clear indication for irradiated components. What do you do?

My first priority would be to assess the patient and clarify exactly what was transfused, when, and what risk it creates. I would inform the haematology consultant, transfusion laboratory and transfusion practitioner immediately. I would follow the local transfusion incident pathway and ensure appropriate monitoring and follow-up.

The patient should receive an honest explanation and apology in line with duty of candour. I would not speculate or assign blame before the facts were clear, but I would not minimise the error. The incident would need investigation, including whether the issue arose from prescribing, laboratory flags, special requirement documentation or bedside checks. The purpose is to protect the patient and prevent recurrence.

A patient with lymphoma refuses chemotherapy and wants to pursue alternative therapy instead. How do you manage the consultation?

I would approach the conversation without dismissiveness. I would explore what the patient understands about the lymphoma, what they hope the alternative therapy will achieve, and what concerns they have about chemotherapy. I would then explain the expected benefits and risks of standard treatment, the risks of delaying or declining it, and any known harms or interactions from the alternative therapy.

If the patient has capacity, they are entitled to refuse treatment, even if I disagree. However, the decision must be informed. I would involve the consultant and clinical nurse specialist, offer written information and arrange follow-up. I would try to maintain the therapeutic relationship, because a patient who feels judged may disengage entirely, whereas a patient who feels heard may reconsider or continue to accept supportive care.

A patient with thrombocytopenia needs a lumbar puncture for suspected CNS lymphoma, but their platelet count is 28 x 10^9/L. How do you approach this?

I would balance diagnostic urgency against bleeding risk. A lumbar puncture in significant thrombocytopenia carries a risk of spinal haematoma, so I would not proceed without a clear plan. I would clarify the urgency of CSF assessment, whether imaging has excluded raised intracranial pressure, the platelet trend, coagulation screen, anticoagulant exposure and whether platelet support is available.

I would discuss with senior haematology and the procedural team. If the lumbar puncture is necessary, I would arrange platelet transfusion to an appropriate threshold according to local policy and ensure post-procedure monitoring. If it is not immediately essential, I would delay until safer. The answer should show that I am not simply quoting a number, but thinking about the whole procedural risk.

A patient with sickle cell disease says previous doctors ignored their pain and they no longer trust the hospital. How do you respond?

I would acknowledge their experience directly and avoid becoming defensive. Pain in sickle cell disease can be severe, and delayed analgesia is harmful. I would ask what normally helps, check whether they have an individualised pain plan, and ensure prompt analgesia while assessing for complications such as acute chest syndrome, infection, stroke or splenic sequestration.

I would explain what I am doing and when I will reassess pain. I would involve the sickle cell team if available. Rebuilding trust requires consistent actions: listening, treating pain promptly, following through on what I say, and being transparent about the plan. A strong answer should show both clinical vigilance and awareness of the bias patients with sickle cell disease may encounter.

A patient has a pulmonary embolism but also platelets of 18 x 10^9/L after chemotherapy. How would you manage anticoagulation?

This is a high-risk balance between thrombosis and bleeding, and I would involve the haematology consultant urgently. I would assess the extent and severity of the pulmonary embolism, whether the patient is haemodynamically stable, the platelet trend, bleeding symptoms, cause of thrombocytopenia and expected marrow recovery.

Management might include modified-dose anticoagulation, platelet-supported anticoagulation, temporary withholding in extreme bleeding risk, or discussion of other measures in selected cases. The exact decision depends on the clinical context and local policy. I would document the reasoning carefully and review frequently, because the balance may change as platelets recover or thrombosis evolves.

A colleague tells you they are struggling in training and asks you not to tell anyone. What do you do?

I would listen carefully and thank them for trusting me. I would ask what they are finding difficult, whether there are immediate patient safety concerns, and whether they feel at risk of harm themselves. If there is no immediate safety issue, I would encourage them to speak to their educational supervisor, clinical supervisor, GP, occupational health or another trusted senior.

I would not automatically breach confidence, but I would be clear that if I believed patients or the colleague were at serious risk, I would need to involve appropriate support. I would offer to help them access support rather than leaving them alone with the problem. The best answer is compassionate but not passive: supporting colleagues is part of patient safety.

A patient asks you to guarantee that stem cell transplant will cure them before they consent. How do you respond?

I would explain that I cannot honestly guarantee cure, and that valid consent depends on balanced information rather than reassurance at any cost. I would explore what they mean by guarantee and what they are most worried about. I would then explain the purpose of transplant, the realistic chance of cure or disease control, and the major risks, including treatment-related mortality, graft-versus-host disease, infection, infertility and long-term complications.

I would involve the transplant consultant and specialist nurse, provide written information and allow time for questions. If the patient remains unsure, that is not a failure. It may mean they need further discussion before making a decision. The key is to preserve trust by being honest about uncertainty.

You disagree with an oncology consultant who wants to continue chemotherapy in a patient you think is too frail. What do you do?

I would approach the disagreement respectfully and focus on the patient’s interests. I would clarify the treatment aim, expected benefit, toxicity risk, performance status, comorbidities and the patient’s own goals. I would present my concerns using specific clinical facts rather than personal judgement.

If disagreement remained, I would suggest discussion at MDT, consultant-to-consultant review or a second opinion if appropriate. I would not undermine the oncology consultant in front of the patient, but I also would not remain silent if I believed treatment could cause disproportionate harm. Professional disagreement is acceptable when handled openly, documented clearly and centred on patient benefit.

Haematology ST3 Interview Prep Services

Optimise Your Interview Preparation with our free resources or prepare in your own time with our Interview Question Bank & Online Course

What Assessors Are Looking For

In hard Haematology ST3 interview questions, assessors are looking for candidates who can hold complexity without becoming vague. You should avoid absolutist answers unless the principle is genuinely absolute, such as respecting a capacitous refusal. In most scenarios, the strongest response is balanced: assess the patient, identify the risk, involve seniors early, communicate honestly, document clearly and review the situation as it evolves.

Preparing for the Haematology ST3 interview? Blackstone Tutors offers a dedicated Haematology ST3 preparation course with 210 model questions and answers, structured across clinical, ethical, communication and professional judgement domains.

Shopping Cart
Powered By MemberPress WooCommerce Plus Integration
Scroll to Top

Intensive BMAT Course

BMAT Timetable

The BMAT Course